SKIN B-CELL LYMPHOMAS: 20 YEARS EXPERIENCE IN OBSERVATION AND TREATMENT

Abstract

Authors observed 18 patients with cutaneous B-cell lymphomas (B-CLS): primary cutaneous follicle center lymphoma (PCFCL) (44,45%), primary diffuse large B-cell lymphoma (B-CLL) (44,45%), cutaneous marginal zone B-cell lymphoma (CMZL) (11,1%). Features of cutaneous marginal zone B-cell lymphoma are: appearance of multiple spots; identification of diagnosis in stages T2aN0M0; treatment - excision or laser destruction; frequent recurrence do not affect prognosis. Features of primary cutaneous follicle center lymphoma are: appearance of single node; identification of diagnosis in stages T1aN0M0 and T2aN0M0; treatment - excision, can be also combined with radiotherapy. Features of primary diffuse B-CLL are: appearance of multiple spots; identification of diagnosis in stages T3bN0M0, T1aN1M0 and T2bN2M0; disease is aggressive; treatment is a local radiotherapy, interferon alpha intralesional, chemotherapy according to schemes CHOP, COP and R-CHOP, photodynamic therapy is possible.

Keywords

cutaneous B-cell lymphomas / TNM staging system / clinical features / staging and treatment

References

[1] Willemze R., Jaffe E.S., Burg G., Cerroni L., Berti E., Swerdlow S.H., et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005; 105(10): 3768-85.

[2] Swerdlov S.H., Campo E., Harris N.L., Jaffe E.S., Pileri S.A., Stein H., et al., eds. WHO classification of tumours of haematopoietic and lymphoid tissues (IARC WHO Classification of Tumours). 4th ed. Lyon; 2008.

[3] Kim Y.H., Willemze R., Pimpinelli N., Whittaker S., Olsen E.A., Ranki A., et al. TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007; 110(2): 479-84.

[4] Golling P., Cozzio A., Dummer R., French L., Kempf W. Primary cutaneous B-cell lymphoma: Clinicopathological, prognostic and therapeutic characterization of 54 cases. Leuk. Lymphoma. 2008; 49(6): 1094-103.

[5] Onsun N., Su O., Kural Y.B., Erdemoglu Y., Buyukbabani N., Demirkesen C., Aydin Y. Primary cutaneous B-cell lymphoma: subtypes, treatment and outcome of 10 cases. Acta Derm. Venereol. 2011; 91(4): 476-8.

[6] Рукавицын О.А., Поп В.П., Агеева Т.А., Архипова Н.В., Байков В.В., Ламоткин И.А. и др. Гематология. Национальное руководство. М.: ГЭОТАР-Медиа; 2015.

[7] Самцов А.В., Белоусова И.Э. Клинические, гистологические и иммуногистохимические особенности лимфом кожи на современном этапе. Вестник дерматологии и венерологии. 2006; 1: 3-6.

[8] Baldassano M.F., Bailey E.M., Ferry J.A., Harris N.L., Duncan L.M. Cutaneous lymphoid hyperplasia and cutaneous marginal zone lymphoma: comparison of morphologic and immunophenotypic features. Am. J. Surg. Pathol. 1999; 23(1): 88-96

[9] Ламоткин И.А. Онкодерматология. Атлас. Учебное пособие. М.: Лаборатория знаний; 2017.

[10] Минимальные клинические рекомендации Европейского Общества Медицинской Онкологии (ЕSMO). М.: РОНЦ им. Н. Н. Блохина РАМН; 2010.

[11] Ламоткин И.А. Опухоли и опухолеподобные поражения кожи. Атлас. М.: БИНОМ, Лаборатория знаний; 2006.

[12] Ламоткин И.А., Капустина О.Г., Бурлаченко О.В., Волгин В.Н. Клиника, диагностические методы исследования, лечение и прогноз В- и Т-клеточных лимфом кожи. Альманах клинической медицины. 2006; 9: 54-9.

[13] Ламоткин И.А. Клиническая дерматоонкология. Атлас. Учебное пособие. М.: Бином, Лаборатория знаний; 2011.

[14] Yang B., Tubbs R.R., Finn W., Carlson A., Pettay J., Hsi E.D. Clinicopathologic reassessment of primary cutaneous B-cell lymphomas with immunophenotypic and molecular genetic characterization. Am. J. Surg. Pathol. 2000; 24(5): 694-702.

[15] Pandolfino T.L., Siegel R.S., Kuzel T.M., Rosen S.T., Guitart J. Primary cutaneous B-cell lymphoma: review and current concepts. J. Clin. Oncol. 2000; 18(10): 2152-68.

[16] Goodlad J.R., Krajewski A.S., Batstone P.J., McKay P., White J.M., Benton E.C., et al. Primary cutaneous diffuse large B-cell lymphoma: prognostic significance of clinicopathological subtypes. Am. J. Surg. Pathol. 2003; 27(12): 1538-45.

[17] Hallermann C., Kaune K.M., Siebert R., Vermeer M.H., Tensen C.P., Willemze R. Chromosomal aberration patterns differ in subtypes of primary cutaneous B-cell lymphomas. J. Invest. Dermatol. 2004; 122(6): 1495-502.

[18] Hallermann C., Kaune K.M., Gesk S., Martin-Subero J.I., Gunawan W.B., Griesinger Z.F., et al. Molecular cytogenetic analysis of chromosomal breakpoints in the IGH, MYC, BCL-6 and MALT1 gene loci in primary cutaneous B-cell lymphomas. J. Invest. Dermatol. 2004; 123(1): 213-9.

[19] Grange F., Bekkenk M.W., Wechsler J., Meijer C.J., Cerroni L., Bernengo M., et al. Prognostic factors in primary cutaneous large B-cell lymphomas: a European multicenter study. J. Clin. Oncol. 2001; 19(16): 3602-10.

RIGHTS & PERMISSIONS

Eco-Vector